Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neurocognitive Effects of Extended-Release Methylphenidate in Healthy Adults
Sponsor: University of Witwatersrand, South Africa
Summary
This study evaluated the effects of methylphenidate (MPH), a stimulant medication commonly used to treat attention deficit hyperactivity disorder (ADHD), in healthy adults without ADHD. Although MPH is sometimes used by students and athletes to improve concentration or performance, its true benefits and risks in healthy individuals are uncertain. The purpose of this study was to determine whether short-term use of MPH improves thinking ability, physical performance, cardiovascular function, balance, muscle strength, or heart safety in healthy adults. In this randomized, double-blind, placebo-controlled crossover study, 28 healthy adult participants received either MPH (20 mg daily) or a placebo for 14 days, followed by a washout period and then the alternate treatment. Participants underwent repeated testing of heart rate, blood pressure, exercise capacity, balance, muscle strength, cognitive function, and heart electrical activity (ECG).
Official title: The Neurocognitive Effects of Extended-Release Methylphenidate in Healthy Adults: A Review and Placebo-Controlled Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-02-06
Completion Date
2024-04-15
Last Updated
2026-08-03
Healthy Volunteers
Yes
Conditions
Interventions
Methylphenidate Stimulant medication therapy
Extended-release methylphenidate 20 mg administered orally once daily for 14 days.
Placebo Capsule(s)
Matching placebo capsules containing inert sucrose, identical in appearance to the active medication capsules.
Locations (1)
University of the Witwatersrand
Johannesburg, Gauteng, South Africa